US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Eli Lilly (NY:LLY)

1,143.12 +0.27 (+0.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
News headline image
Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. ↗
Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance. 
Via The Motley Fool
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
News headline image
Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. ↗
Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs. 
Via Investor's Business Daily
News headline image
Why Did Eli Lilly Stock Drop Today? ↗
Can Eli Lilly cure cancer? Maybe -- with a little help. 
Via The Motley Fool
ELI LILLY & CO (NYSE:LLY): A High-Quality Dividend Growth Stock for Patient Investors ↗
Via Chartmill
Eli Lilly & Co (NYSE:LLY): A Growth Stock Showing Technical Setup for a Potential Breakout ↗
Via Chartmill
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
Via The Motley Fool
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
Why Legend Biotech Stock Crushed the Market on Monday ↗
Two analysts weighed in positively about the company's future. 
Via The Motley Fool
News headline image
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% ↗
Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025. 
Via MarketBeat
News headline image
Eli Lilly Goes Atomic—But This Isn't About AI Servers ↗
Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs. 
Via Investor's Business Daily
News headline image
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? ↗
Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April. 
Via The Motley Fool
News headline image
Eli Lilly (LLY): 3 Reasons We Love This Stock
Eli Lilly currently trades at $926.10 and has been a dream stock for shareholders. It’s returned 386% since April 2021, blowing past the S&P 500’s 70.2% gain... 
Via StockStory
Topics Stocks
News headline image
2 Millionaire-Maker Stocks to Hold for the Next 10 Years ↗
No need for a time machine to profit from these companies. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is This the Biggest Game-Changer in Lilly's 150-Year History? ↗
The company's recent dip may be a buying opportunity. 
Via The Motley Fool
News headline image
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake ↗
Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies. 
Via Benzinga
News headline image
3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
Via MarketBeat
News headline image
Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. ↗
Eli Lilly's oral weight-loss drug, Foundayo, nabbed 1,390 prescriptions in its first week on the market, analysts said Friday. 
Via Investor's Business Daily
News headline image
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
The stock could have plenty of room to run from current levels. 
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗
There are other factors to consider before investing in this -- or any other -- healthcare company. 
Via The Motley Fool
News headline image
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗
MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data. 
Via Benzinga
News headline image
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? ↗
It's acquiring an asset with a very promising lead drug candidate. 
Via The Motley Fool
News headline image
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar ↗
Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data. 
Via Benzinga
News headline image
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗
Lilly's revenue has soared thanks to its obesity drugs. 
Via The Motley Fool
News headline image
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗
And can Novo Nordisk catch up to its rival in the weight loss market? 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >